University of Western Australia

www.uwa.edu.au/
Perth, Australia

The University of Western Australia is a research-intensive university in Perth, Australia that was established by an act of the Western Australian Parliament in February 1911, and began teaching students for the first time in 1913. It is the oldest university in the state of Western Australia and is colloquially known as a "sandstone university". It is also a member of the Group of Eight.UWA was established under and is governed by the University of Western Australia Act 1911. The Act provides for control and management by the university's Senate, and gives it the authority, amongst other things, to make statutes, regulations and by-laws, details of which are contained in the university Calendar.UWA is highly ranked internationally in various publications: the 2013/14 QS World University Rankings placed UWA at 84th internationally, and in August 2014 the The Academic Ranking of World Universities from Shanghai Jiao Tong University placed the university at 88th in the world. To date, the university has produced 100 Rhodes Scholars, 1 Nobel Prize laureate and 1 Australian Prime Minister graduated from UWA.UWA recently joined the Matariki Network of Universities as the youngest member, the only one established during the 20th century. Wikipedia.


Time filter

Source Type

Patent
University of Western Australia | Date: 2014-09-12

An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.


Patent
Proteomics International Pty Ltd and University of Western Australia | Date: 2017-04-05

The invention provides biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement Clq subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.


Patent
The Research Institute At Nationwide Childrens Hospital and University of Western Australia | Date: 2017-06-21

The present invention relates to the delivery of oligomers for treating patients with a 5 mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5 mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.


Patent
University of Western Australia | Date: 2017-01-25

A recombinant polypeptide is described which comprises at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide comprises at least one RNA base-binding motif of the general formula X_(1)X_(2)X_(3)X_(4)X_(5)X_(6)X_(7)X_(8)X_(9)X_(10)X_(11 )wherein X_(1 )is selected from the group including glutamine (Q), valine (V), methionine (M), proline (P), glutamic acid (E), and lysine (K); X_(2 )is selected from the group including histidine (H), phenylalanine (F), tyrosine (Y), and asparagine (N); X_(3 )is selected from the group including glycine (G) and alanine (A); X_(4 )is selected from the group including glycine (G), alanine (A), serine (S), threonine (T) and cysteine (C); X_(5 )is selected from the group including arginine (R), tyrosine (Y), histidine (H), and asparagine (N); X_(6 )is selected from the group including phenylalanine (F), leucine (L), and valine (V); X_(7 )is selected from the group including isoleucine (I), leucine (L), and valine (V); X_(8 )is arginine (R); X_(9 )is selected from the group including leucine (L), lysine (K), arginine (R), glutamine (Q), and histidine (H); X_(10 )is selected from the group including lysine (K), phenylalanine (F), alanine (A), cysteine (C), isoleucine (I), valine (V), leucine (L), and methionine (M); and X_(11 )is selected from the group including leucine (L), phenylalanine (F), isoleucine (I), and valine (V); and wherein the RNA base-binding motif is operably capable of specifically binding to a cytosine RNA base.


Patent
University of Western Australia | Date: 2017-07-26

Provided herein are methods for modulating tumour stroma, normalizing tumour vasculature and/or improving vascular function in a tumour, comprising exposing a tumour to an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide. Also provided are methods for treating tumours and increasing the survival time of tumour-bearing patients, comprising administering an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide. Also provided are methods for treating tumours and extending survival of tumour-bearing patients comprising administering an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide in combination with one or more immunotherapeutic agents.


Patent
University of Western Australia and Telethon Kids Institute | Date: 2017-07-26

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.


Patent
Research Institute At Nationwide Childrens Hospital and University of Western Australia | Date: 2015-08-07

The present invention relates to the delivery of oligomers for treating patients with a 5 mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5 mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.


Patent
University of Western Australia and Telethon Kids Institute | Date: 2015-07-31

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.


Barkan A.,University of Oregon | Small I.,University of Western Australia
Annual Review of Plant Biology | Year: 2014

Pentatricopeptide repeat (PPR) proteins constitute one of the largest protein families in land plants, with more than 400 members in most species. Over the past decade, much has been learned about the molecular functions of these proteins, where they act in the cell, and what physiological roles they play during plant growth and development. A typical PPR protein is targeted to mitochondria or chloroplasts, binds one or several organellar transcripts, and influences their expression by altering RNA sequence, turnover, processing, or translation. Their combined action has profound effects on organelle biogenesis and function and, consequently, on photosynthesis, respiration, plant development, and environmental responses. Recent breakthroughs in understanding how PPR proteins recognize RNA sequences through modular base-specific contacts will help match proteins to potential binding sites and provide a pathway toward designing synthetic RNA-binding proteins aimed at desired targets. Copyright © 2014 by Annual Reviews.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-04-2016 | Award Amount: 10.41M | Year: 2017

Early life is an important window of opportunity to improve health across the full lifecycle. European pregnancy and child cohort studies together offer an unique opportunity to identify a wide range of early life stressors linked with individual biological, developmental and health trajectory variations, and to the onset and evolution of non-communicable diseases. LIFECYCLE will establish the EuroCHILD Cohort Network, which brings together existing, successful pregnancy and child cohorts and biobanks, by developing a governance structure taking account of national and European ethical, legal and societal implications, a shared data-management platform and data-harmonization strategies. LIFECYCLE will enrich this EuroCHILD Cohort Network by generating new integrated data on early life stressors related to socio-economic, migration, urban environment and life-style determinants, and will capitalize on these data by performing hypothesis-driven research on early life stressors influencing cardio-metabolic, respiratory and mental health trajectories during the full lifecycle, and the underlying epigenetic mechanisms. LIFECYCLE will translate these results into recommendations for targeted strategies and personalized prediction models to improve health trajectories for current and future Europeans generations by optimizing their earliest phase of life. To strengthen this long-term collaboration, LIFECYCLE will organize yearly international meetings open to pregnancy and child cohort researchers, introduce a Fellowship Training Programme for exchange of junior researchers between European pregnancy or child cohorts, and develop e-learning modules for researchers performing life-course health studies. Ultimately, LIFECYCLE will lead to a unique sustainable EuroCHILD Cohort Network, and provide recommendations for targeted prevention strategies by identification of novel markers of early life stressors related to health trajectories throughout the lifecycle.

Loading University of Western Australia collaborators
Loading University of Western Australia collaborators